新股消息 | 藥明巨諾計劃週四就香港IPO尋求上市批准
彭博報道,據IFR引述接近交易的人士報道,細胞療法公司JW Therapeutics(藥明巨諾)計劃週四就約2億至3億美元香港IPO申請上市批准。
高盛和瑞銀是此次IPO的聯席保薦人。
JW Therapeutics(藥明巨諾)由Juno Therapeutics和藥明康德於2016年在上海成立。
根據初步招股書,JW Therapeutics(藥明巨諾)是全球領先的臨牀階段細胞治療平台公司,主打候選產品elmacabtagene autoleucel(「relma-cel」)是針對復發或難治(「r/r」)B細胞淋巴瘤的抗CD19 CAR-T療法,且國家藥監局已於2020年6月受理審查將relmacel用作DLBCL三線療法的新藥申請。Relma-cel有望成爲中國首個獲批的一類生物製品CAR-T療法,並有望成爲同類最佳CAR-T療法。
uSMART早前報道:
《新股消息 | 藥明康德、淡馬錫投資的JW(Cayman)向港交所遞表》
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.